Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 233

1.

Autoantibody profiling in intraocular fluid of patients with uveitis.

Ten Berge JC, Schreurs MW, van Rosmalen J, Rothova A.

Exp Eye Res. 2018 Jul 10;176:141-146. doi: 10.1016/j.exer.2018.07.012. [Epub ahead of print]

PMID:
30006272
2.

Complex interaction between mutant HNRNPA1 and gE of varicella zoster virus in pathogenesis of multiple sclerosis.

Kattimani Y, Veerappa AM.

Autoimmunity. 2018 Jun;51(4):147-151. doi: 10.1080/08916934.2018.1482883. Epub 2018 Jul 11.

PMID:
29996671
3.

The intrathecal polyspecific antiviral immune response (MRZ reaction): A potential cerebrospinal fluid marker for multiple sclerosis diagnosis.

Feki S, Gargouri S, Mejdoub S, Dammak M, Hachicha H, Hadiji O, Feki L, Hammami A, Mhiri C, Karray H, Masmoudi H.

J Neuroimmunol. 2018 Aug 15;321:66-71. doi: 10.1016/j.jneuroim.2018.05.015. Epub 2018 May 28.

PMID:
29957390
4.

A Pediatric Case of Relapsing-Remitting Multiple Sclerosis Onset following Varicella Zoster Ophthalmicus with Optic Neuritis.

Shiba N, Inaba Y, Motobayashi M, Nishioka M, Kawasaki Y, Noda S, Matsuura H, Kobayashi N, Matsuoka T, Nakamura A, Nakazawa Y.

Case Rep Pediatr. 2018 Mar 26;2018:6931206. doi: 10.1155/2018/6931206. eCollection 2018.

5.

Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies.

Guerra H, Pittock SJ, Moder KG, Fryer JP, Gadoth A, Flanagan EP.

Mayo Clin Proc. 2018 Apr 11. pii: S0025-6196(18)30103-4. doi: 10.1016/j.mayocp.2018.02.006. [Epub ahead of print]

PMID:
29655487
6.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23.

PMID:
29576505
7.

The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis.

Hottenrott T, Schorb E, Fritsch K, Dersch R, Berger B, Huzly D, Rauer S, Tebartz van Elst L, Endres D, Stich O.

J Neurol. 2018 May;265(5):1106-1114. doi: 10.1007/s00415-018-8779-x. Epub 2018 Mar 6.

PMID:
29511863
8.

The MRZ reaction helps to distinguish rheumatologic disorders with central nervous involvement from multiple sclerosis.

Hottenrott T, Dersch R, Berger B, Endres D, Huzly D, Thiel J, Rauer S, Stich O, Salzer U, Venhoff N.

BMC Neurol. 2018 Jan 31;18(1):14. doi: 10.1186/s12883-018-1018-3.

9.

Do patients with schizophreniform and bipolar disorders show an intrathecal, polyspecific, antiviral immune response? A pilot study.

Endres D, Huzly D, Dersch R, Stich O, Berger B, Schuchardt F, Perlov E, Venhoff N, Hellwig S, Fiebich BL, Erny D, Hottenrott T, Tebartz van Elst L.

Fluids Barriers CNS. 2017 Dec 7;14(1):34. doi: 10.1186/s12987-017-0082-1.

10.

Cerebral toxoplasmosis in an MS patient receiving Fingolimod.

Enriquez-Marulanda A, Valderrama-Chaparro J, Parrado L, Diego Vélez J, Maria Granados A, Luis Orozco J, Quiñones J.

Mult Scler Relat Disord. 2017 Nov;18:106-108. doi: 10.1016/j.msard.2017.05.004. Epub 2017 May 12.

PMID:
29141790
11.

Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature.

Ruprecht K, Wildemann B, Jarius S.

J Neurol. 2018 Feb;265(2):239-252. doi: 10.1007/s00415-017-8656-z. Epub 2017 Nov 2. Review.

PMID:
29098417
12.

More evidence is needed to show any role of cytomegalovisrus and varicella zoster virus in pathogenesis of multiple sclerosis.

Badihian S, Manouchehri N, Badihian N.

J Neuroimmunol. 2017 Dec 15;313:123-124. doi: 10.1016/j.jneuroim.2017.09.006. Epub 2017 Sep 18. No abstract available.

PMID:
29030049
13.

Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis.

Manouchehrinia A, Tanasescu R, Kareem H, Jerca OP, Jabeen F, Shafei R, Breuer J, Neal K, Irving W, Constantinescu CS.

J Neurovirol. 2017 Dec;23(6):839-844. doi: 10.1007/s13365-017-0569-1. Epub 2017 Sep 11.

14.

Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis.

Jarius S, König FB, Metz I, Ruprecht K, Paul F, Brück W, Wildemann B.

J Neuroinflammation. 2017 Aug 29;14(1):171. doi: 10.1186/s12974-017-0929-z.

16.

Clinical commentary on "Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab".

Salmen A.

Mult Scler. 2018 Mar;24(3):360-362. doi: 10.1177/1352458517717810. Epub 2017 Jun 23. No abstract available.

PMID:
28643548
17.

Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.

Mulero P, Auger C, Parolin L, Fonseca E, Requena M, Rio J, Tintoré M, Rovira A, Montalban X.

Mult Scler. 2018 Mar;24(3):358-360. doi: 10.1177/1352458517711569. Epub 2017 Jun 23.

PMID:
28643544
18.

A case of presumed herpes keratouveitis in a patient treated with fingolimod.

Ayers MC, Conway DS.

Mult Scler J Exp Transl Clin. 2016 Jun 3;2:2055217316652907. doi: 10.1177/2055217316652907. eCollection 2016 Jan-Dec.

19.

Cytomegalovirus and varicella zoster virus seropositivity of Iranian patients with multiple sclerosis: A population-based study.

Karampoor S, Zahednasab H, Ramagopalan S, Mehrpour M, Etemadifar M, Alsahebfosoul F, Keyvani H.

J Neuroimmunol. 2017 Aug 15;309:4-6. doi: 10.1016/j.jneuroim.2017.04.004. Epub 2017 Apr 8.

PMID:
28601285
20.

The MRZ reaction in primary progressive multiple sclerosis.

Hottenrott T, Dersch R, Berger B, Rauer S, Huzly D, Stich O.

Fluids Barriers CNS. 2017 Feb 7;14(1):2. doi: 10.1186/s12987-016-0049-7.

Supplemental Content

Loading ...
Support Center